ArticleClinical rheumatology2020
Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- IL-34 aggravates myocardial ischemia-reperfusion injury by upregulating the HMGB1-IL-17A-IL-6 axis through the JAK signaling pathway.PloS one · 2025Article
- Nerve Growth Factor and Autoimmune Diseases.Current issues in molecular biology · 2023Review
- The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the workTo determine the role of Interleukin-34 (IL-34) in the pathogenesis of juvenile systemic lupus erythematosus (J-SLE), by exploring the relationship between IL-34 concentration and the disease activity SUBJECTS AND
methodsThis study was carried out on 48 children with SLE, and 30 healthy control subjects. SLE disease activity was measured by systemic lupus erythematosus disease activity index (SLEDAI). Serum IL-34 was measured by enzyme-linked immunosorbent assay (ELISA). The collected data were statistically analyzed using SPSS program version 16.0.
resultsThere was a significant elevation in IL-34 concentration in J-SLE patients (52.25 ± 19.94 pg/ml) compared with control group (11.20 ± 6.40 pg/ml) (p < 0.001). The highest level was detected in patients with high SLEDAI score and with lupus nephritis (p = 0.005, 0.003, respectively). There was a statistically significant positive correlation between IL-34 levels and SLEDAI, ESR, CRP, and anti-ds DNA antibodies, but negative correlation with complement (C3, C4), and hemoglobin levels in J-SLE patients.
conclusionIL-34 could be a probable marker for J-SLE disease activity which is more aggressive than adult-SLE, and IL-34 blockage may suppress the expression of proinflammatory cytokines in patients' blood.Key Points•Juvenile SLE is more aggressive and of worse prognosis than adult-SLE.• Significantly elevated concentration of IL-34 in juvenile SLE patients when compared with controls.• Elevated concentrations of IL-34 in patients are correlated with SLEDAI, ESR, CRP, ds-DNA antibodies, hemoglobin, and complement levels.• IL-34 may play a role in SLE pathogenesis and disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.